Biomarin Pharmaceutical Inc (BMRN) concluded trading on Thursday at a closing price of $68.73, with 4.35 million shares of worth about $298.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.91% during that period and on February 20, 2025 the price saw a gain of about 4.76%. Currently the company’s common shares owned by public are about 190.76M shares, out of which, 188.15M shares are available for trading.
Stock saw a price change of 4.36% in past 5 days and over the past one month there was a price change of 9.92%. Year-to-date (YTD), BMRN shares are showing a performance of 4.56% which decreased to -22.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $60.63 but also hit the highest price of $94.85 during that period. The average intraday trading volume for Biomarin Pharmaceutical Inc shares is 1.47 million. The stock is currently trading 7.49% above its 20-day simple moving average (SMA20), while that difference is up 5.84% for SMA50 and it goes to -7.76% lower than SMA200.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) currently have 190.76M outstanding shares and institutions hold larger chunk of about 97.79% of that.
The stock has a current market capitalization of $13.10B and its 3Y-monthly beta is at 0.35. PE ratio of stock for trailing 12 months is 31.32, while it has posted earnings per share of $2.19 in the same period. Its PEG reads 1.00 and has Quick Ratio of 3.29 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BMRN, volatility over the week remained 3.10% while standing at 2.50% over the month.
Stock’s fiscal year EPS is expected to rise by 43.47% while it is estimated to increase by 29.78% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on November 15, 2024 offering an Outperform rating for the stock and assigned a target price of $95 to it. On October 10, 2024, Raymond James Resumed their recommendations, while on August 20, 2024, Bernstein Upgrade their ratings for the stock with a price target of $110. Stock get a Neutral rating from Robert W. Baird on May 17, 2024.
